Microbot Medical Inc. (MBOT)
After Plunging 22.6% in 4 Weeks, Here's Why the Trend Might Reverse for Microbot Medical (MBOT)
Microbot Medical (MBOT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Microbot Medical Inc. (MBOT) Shareholder/Analyst Call Transcript
Microbot Medical Inc. (MBOT) Shareholder/Analyst Call Transcript
Microbot Medical Inc. (MBOT) Reports Q1 Loss, Misses Revenue Estimates
Microbot Medical Inc. (MBOT) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.08 per share a year ago.
Microbot Medical Begins Full U.S. Launch of LIBERTY System
MBOT moves to full U.S. launch of its LIBERTY robotic system after strong hospital adoption, boosting momentum for faster market uptake and sales growth.
Down 28.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Microbot Medical (MBOT)
Microbot Medical (MBOT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Microbot Shares Rise on FDA Clearance for LIBERTY Robotic System
MBOT shares rise as FDA clears its LIBERTY robotic system, paving the way for U.S. market entry and fueling strong investor momentum.
Microbot Shares Rise as New U.S. Patent Expands LIBERTY System Market
MBOT's new U.S. patent boosts the LIBERTY system's flexibility, expanding its U.S. market reach to over six million annual procedures.
Microbot Medical (MBOT) Upgraded to Buy: What Does It Mean for the Stock?
Microbot Medical (MBOT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MBOT Stock Gains Following FDA Submission of the LIBERTY System
Microbot Medical announces the submission of its LIBERTY System for FDA marketing clearance.
Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY
Microbot Medical (MBOT) signs a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures using LIBERTY.
Microbot Medical (MBOT) Gets Quality Certification for its System
Microbot Medical (MBOT) secures ISO 13485:2016 certification for its LIBERTY Endovascular Robotic System, a milestone that streamlines European and FDA regulatory compliance for future commercialization.
Microbot Medical (MBOT) Inks Deal to Test Autonomous Robotics
Microbot Medical (MBOT) announces an agreement with Emory University to explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system.
